

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER AND 15 MONTHS ENDED 31 MARCH 2016**

RM'000	3 months ended		15 months ended	
	31.03.16 (Unaudited)	31.03.15 (Unaudited)	31.03.16 (Unaudited)	31.03.15 (Unaudited)
Revenue	1,322	3,518	8,802	8,592
Other income	(14)	63	2,347	205
Operating expenses	(2,119)	(4,557)	(15,742)	(30,301)
Operating loss before tax	<u>(811)</u>	<u>(976)</u>	<u>(4,593)</u>	<u>(21,504)</u>
Taxation	-	-	-	-
Net loss after tax	<u>(811)</u>	<u>(976)</u>	<u>(4,593)</u>	<u>(21,504)</u>
Total comprehensive expense for the period	<u>(811)</u>	<u>(976)</u>	<u>(4,593)</u>	<u>(21,504)</u>
Loss attributable to:				
Owners of the Company	(749)	(999)	(4,268)	(21,126)
Non-controlling interest	(62)	23	(325)	(378)
	<u>(811)</u>	<u>(976)</u>	<u>(4,593)</u>	<u>(21,504)</u>
Total comprehensive expense attributable to:				
Owners of the Company	(749)	(999)	(4,268)	(21,126)
Non-controlling interest	(62)	23	(325)	(378)
	<u>(811)</u>	<u>(976)</u>	<u>(4,593)</u>	<u>(21,504)</u>
Loss per share attributable to Owners of the Company (sen):-				
Basic	(0.15)	(0.20)	(0.86)	(4.45)
Fully diluted*	<u>(0.15)</u>	<u>(0.20)</u>	<u>(0.86)</u>	<u>(4.45)</u>

\* The diluted loss per share of the Group is equivalent to the basic loss per share as the diluted loss per share has anti-dilutive effect.

*The above condensed consolidated statements of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 MARCH 2016**

<b>RM'000</b>	<b>As at 31.03.16 (Unaudited)</b>	<b>As at 31.12.14 (Audited)</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	15,213	28,540
	<u>15,213</u>	<u>28,540</u>
<b>Current assets</b>		
Inventories	532	799
Trade receivables	927	3,267
Other receivables, deposits and prepayments	1,291	1,310
Tax recoverable	55	55
Fixed deposits with licensed bank	368	357
Cash on hand and at banks	976	1,261
Asset classified as held for sale	10,702	1,491
	<u>14,851</u>	<u>8,540</u>
<b>TOTAL ASSETS</b>	<u>30,064</u>	<u>37,080</u>
<b>EQUITY AND LIABILITIES</b>		
Share capital	99,732	99,732
Accumulated losses	(75,291)	(71,023)
Other reserves	2,381	2,381
Equity attributable to Owners of the Company	26,822	31,090
Non-controlling interest	(1,042)	(717)
<b>TOTAL EQUITY</b>	<u>25,780</u>	<u>30,373</u>
<b>Current liabilities</b>		
Trade payables	501	2,976
Other payables and accruals	3,783	3,731
<b>TOTAL LIABILITIES</b>	<u>4,284</u>	<u>6,707</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u>30,064</u>	<u>37,080</u>
Net assets per share attributable to owners of the Company (RM)	<u>0.0538</u>	<u>0.0623</u>

*The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE 15 MONTHS ENDED 31 MARCH 2016**

	<----- Attributable to Owners of the Company ----->					Total	Non- controlling Interest	Total Equity
	Share Capital	Distributable Accumulated losses	<----- Non-Distributable ----->		Warrants Reserve			
	RM '000	RM '000	Share Premium RM '000	ICPS RM '000		RM '000	RM '000	RM '000
Balance as of 1 Jan 2015	99,732	(71,023)	288	-	2,093	31,090	(717)	30,373
Total comprehensive expense for the period	-	(4,268)	-	-	-	(4,268)	(325)	(4,593)
Balance as of 31 March 2016	99,732	(75,291)	288	-	2,093	26,822	(1,042)	25,780
Balance as of 1 Jan 2014	71,072	(50,896)	2,853	19,613	2,093	44,735	(316)	44,419
Conversion of ICPS	20,000	-	-	(19,613)	-	387	-	387
Issuance of shares	8,660	-	-	-	-	8,660	-	8,660
Shares issuance expenses	-	-	(2,565)	-	-	(2,565)	-	(2,565)
Total comprehensive expense for the period	-	(21,126)	-	-	-	(21,126)	(378)	(21,504)
Balance as of 31 March 2015	99,732	(72,022)	288	-	2,093	30,091	(694)	29,397

*The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE 15 MONTHS ENDED 31 MARCH 2016**

<b>RM'000</b>	<b>15 months ended</b>	
	<b>31.03.16</b>	<b>31.03.15</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
<b>CASH FLOWS USED IN OPERATING ACTIVITIES</b>		
Loss before taxation	(4,593)	(21,504)
Adjustments for:		
Bad debts written off	-	51
Deposits written off	47	28
Depreciation of property, plant and equipment	2,874	3,997
Impairment loss on property, plant and equipment	-	9,869
Impairment loss on trade receivables	-	1,936
Property, plant and equipment written off	-	6
Gain on disposal of property, plant and equipment	(1,516)	(12)
Reversal of impairment loss on trade receivables	(460)	(25)
Interest income	(11)	(19)
Unrealised gain on foreign currency exchange	(153)	(75)
<b>Operating loss before working capital changes</b>	<b>(3,812)</b>	<b>(5,748)</b>
Decrease in inventories	267	549
Decrease/(increase) in receivables	2,772	(4,727)
(Decrease)/increase in payables	(2,423)	2,172
Cash absorbed by from operations	(3,196)	(7,754)
Interest received	-	4
<b>Net cash used in operating activities</b>	<b>(3,196)</b>	<b>(7,750)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	(254)	(250)
Proceeds from disposal of property, plant and equipment	3,012	12
<b>Net cash from/(used in) investing activities</b>	<b>2,758</b>	<b>(238)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issuance of ordinary shares	-	8,660
Advances from a shareholder of a subsidiary	-	566
Shares issuance expenses paid	-	(2,565)
<b>Net cash from financing activities</b>	<b>-</b>	<b>6,661</b>
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>	<b>(438)</b>	<b>(1,327)</b>
<b>EFFECT OF EXCHANGE RATE CHANGES</b>	<b>153</b>	<b>29</b>
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b>	<b>1,261</b>	<b>2,277</b>
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>976</b>	<b>979</b>
<b>CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD COMPRISE:</b>		
Cash and bank balances	976	979
Fixed deposit with licensed banks	368	360
	1,344	1,339
Less : Fixed deposit pledged to licensed banks	(368)	(360)
	976	979

*The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2014 and the accompanying explanatory notes attached to these interim financial statements.*

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**NOTES TO THE QUARTERLY REPORT ON CONSOLIDATED RESULT FOR THE QUARTER AND 15 MONTHS ENDED 31 MARCH 2015.**

**A1. BASIS OF PREPARATION**

This condensed consolidated interim financial statements (Condensed Report), other than for financial instruments, have been prepared under the historical cost convention. Certain financial instruments have been carried at fair value in accordance to Malaysian Financial Reporting Standard (MFRS) 139 Financial Instruments: Recognition and Measurement.

This condensed consolidated interim financial statements (Condensed Report) have been prepared in accordance with MFRS 134: Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

This Condensed Report should be read in conjunction with the audited financial statements for the financial period ended 31 December 2014. The explanatory notes attached to the Condensed Report provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2014.

**A2. SIGNIFICANT ACCOUNTING POLICIES**

The accounting policies adopted in the preparation of the Condensed Report are consistent with those followed in the preparation of the Group's audited financial statements for the financial period ended 31 December 2014, except for the adoption of Amendments to Standards and Issue Committee (IC) interpretations effective as of 1 January 2015.

Adoption of Amendments to Standards and IC Interpretations

The Group has adopted the following Amendments to Standards and IC Interpretations, with a date of initial application of 1 January 2015.

Amendments to MFRS 119	Defined Benefit Plans: Employee Contributions
Annual Improvements to MFRSs 2010 - 2012 Cycle	
Annual Improvements to MFRSs 2011 - 2013 Cycle	

The adoption of the above pronouncements did not have any impact on the financial statements of the Group.

Standards issued but not yet effective

At the date of authorisation of the Condensed Report, the following Standards, Amendments and Annual Improvements to Standards were issued by the Malaysian Accounting Standards Board (MASB) but are not yet effective and have not been adopted by the Group:

**Effective for financial periods beginning on or after 1 January 2016**

MFRS 14	Regulatory Deferral Accounts
Amendments to MFRS 11	Accounting for Acquisitions of Interest in Joint Operations
Amendments to MFRS 101	Presentation of Financial Statements - Disclosure Initiative
Amendments to MFRS 127	Equity Method in Separate Financial Statements
Amendments to MFRS 10 and MFRS 128	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**A2. SIGNIFICANT ACCOUNTING POLICIES (CONT'D)**

Standards issued but not yet effective (cont'd)

**Effective for financial periods beginning on or after 1 January 2016 (cont'd)**

Amendments to MFRS 116 and MFRS 138	Clarification of Acceptable Methods of Depreciation and Amortisation
Amendments to MFRS 116 and MFRS 141	Property, plant and equipment - Agriculture: Bearer Plants
Amendments to MFRS 10, MFRS 12 and MFRS 128	Investment Entities: Applying the Consolidation Exception
Annual Improvements to MFRSs 2012 - 2014 Cycle	

**Effective for financial periods beginning on or after 1 January 2018**

MFRS 9	Financial Instruments (IFRS 9 issued by International Accounting Standards Board (IASB) in July 2014)
MFRS 15	Revenue from Contracts with Customers

The Group will adopt the above pronouncements when they become effective in the respective financial periods. The Group does not expect any material impact to the financial statements on the above pronouncements other than for the two Standards described below, for which the effects are still being assessed:

**MFRS 15 Revenue from Contracts with Customers**

MFRS 15 Revenue from Contracts with Customers was issued in September 2014 and establishes a new five-step model that will apply to recognition of revenue arising from contracts with customers. Under this Standard, revenue is recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The principle of this Standard is to provide a more structured approach to measuring and recognising revenue.

This Standard is applicable to all entities and will supersede all current revenue recognition requirements under MFRS. Either a full or modified retrospective application is required for annual periods beginning on or after 1 January 2017 with early adoption permitted.

**MFRS 9 Financial Instruments**

In November 2014, the MASB issued the final version of MFRS 9 Financial Instruments, replacing MFRS 139. This Standard made changes to the requirements for classification and measurement, impairment, and hedge accounting. The adoption of this Standard will have an effect on the classification and measurement of the Group's financial assets, but no impact on the classification and measurement of the Group's financial liabilities.

MFRS 9 Financial Instruments also requires impairment assessments to be based on an expected loss model, replacing the MFRS 139 incurred loss model. Finally, MFRS 9 Financial Instruments aligns hedge accounting more closely with risk management, establish a more principle-based approach to hedge accounting and address inconsistencies and weaknesses in the previous model.

This Standard will come into effect on or after 1 January 2018 with early adoption permitted. Retrospective application is required, but comparative information is not compulsory.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**A3. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS**

The preceding financial period's audited financial statements of the Group were not subject to any qualification.

**A4. SEASONAL AND CYCLICAL FACTORS**

The business operations of the Group are subject to the forces of supply and demand, and thus could display cyclical trends.

**A5. UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS**

There were no material items of an unusual nature and amount for the current quarter and 15 months ended 31 March 2016 under review.

**A6. MATERIAL ESTIMATES AND CHANGES IN ESTIMATES**

There were no material changes in the estimates used in the current quarter and 15 months ended 31 March 2016.

**A7. ISSUANCES, CANCELLATIONS, REPURCHASES, RESALE AND REPAYMENTS OF DEBT AND EQUITY SECURITIES**

There were no issuance and repayment of debt and equity securities, share buy-backs, share cancellations and resale of treasury shares for the current quarter and 15 months ended 31 March 2016.

**A8. DIVIDEND PAID**

There were no dividends paid during the current and previous corresponding quarter.

**A9. SEGMENTAL INFORMATION**

Segment information is primarily presented in respect of the Group's business segment which is based on the Group's management and internal reporting structure. Management monitors the operating results of its business segment separately for the purpose of making decision about resource allocation and performance assessment.

(a) Business segment

The principal activities of the Group are those engaged in business of processing, manufacturing and selling drinking water which are substantially within a single business segment. As such, segmental reporting by business segment is deemed not necessary.

(b) Other segment

No other segmental information such as geographical segment, segment assets, segment liabilities and segment results is presented as the Group is principally involved in the manufacturing industry and operates from Malaysia only.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**A9. SEGMENTAL INFORMATION (CONT'D)**

(c) Major customers

Revenue from major customers with revenue equal or more than 10% of the Group revenue are as follows:

	3 months ended		15 months ended	
	31.03.16	31.03.15	31.03.16	31.03.15
Major customers				
- Customer A	-	1,187	1,187	2,343
- Customer B	-	953	953	1,870
- Customer C	-	504	504	1,019
- Customer D	344	169	1,984	691
- Customer E	-	26	66	621
- Customer F	-	46	112	163
- Customer G	-	-	158	-
- Customer H	246	-	414	-

**A10. VALUATION OF PROPERTY, PLANT AND EQUIPMENT**

There were no revaluation of property, plant and equipment during the quarter and 15 months ended 31 March 2016.

**A11. EVENTS AFTER THE REPORTING PERIOD**

There was no material event subsequent to the end of the reporting period, other than as disclosed in Note B8 of the Notes to the Quarterly Report.

**A12. RELATED PARTY TRANSACTION**

There were no material related party transaction during the quarter and 15 months ended 31 March 2016.

**A13. CHANGES IN THE COMPOSITION OF THE GROUP**

There were no changes in the composition of the Group during the quarter and 15 months ended 31 March 2016.

**A14. CONTINGENT LIABILITIES AND CONTINGENT ASSETS**

There were no contingent liabilities and assets as at the date of this report.

**A15. CAPITAL COMMITMENT**

There were no capital commitment by the Group during the financial period under review.



**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES**

**B1. REVIEW OF PERFORMANCE**

For the current quarter under review, the Group registered a revenue of RM1.322 million compared with RM3.518 million during the corresponding period last year. The drop in sales was due to lower sales of bottled drinking water during the period. The production level was still below the optimum level to achieve profitability, resulting in an operating loss of RM0.811 million at Group level during the current quarter.

The significant drop in sales has resulted the Group to suffer higher losses compared to the corresponding period last year.

**B2. MATERIAL CHANGES IN LOSS BEFORE TAXATION AGAINST THE IMMEDIATE PRECEDING QUARTER**

For the current quarter under review, the Group reported marginal decrease in revenue to RM1.322 million, compared with RM1.494 million recorded during the immediate preceding quarter. The Group continued to suffer a loss after tax of RM0.811 million during the quarter, against loss after taxation of RM1.759 million during the immediate preceding quarter.

**B3. CURRENT PROSPECTS**

The Group has seen some trend stability in the sales of bottled drinking water. With continued efforts from all parties, the management opined that the business will be sustainable going forward. However, the Board remains cautious of the Malaysian economic conditions, as well as pricing competitions amongst the major bottled drinking water players. The Group's thrust will continue to be in Singapore due to our geographical advantage as our plant is located in the state of Johor.

On 24 February 2016, the Group successfully received the shareholders' consent to venture into hospitality and hotel management business via an Extraordinary General Meeting. The Group expects the exercise to be completed within the next two months. This diversification plan will position the Group to gradually expand its revenue and earnings base into the hospitality business which is more stable in nature. The Board and management are hopeful to see an imminent recovery in group performances in the future.

**B4. PROFIT FORECAST**

There was no profit forecast for the period under review was required.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**B5. LOSS BEFORE TAXATION**

Loss before taxation have been determined after charging/(crediting) amongst other items the following:-

RM '000	3 months ended		15 months ended	
	31.03.16	31.03.15	31.03.16	31.03.15
Bad debts written off	-	-	-	51
Deposits written off	19	28	47	28
Depreciation of property, plant and equipment	575	572	2,874	3,997
Bad debts recovered	-	-	-	-
Impairment loss on trade receivables	-	-	-	1,936
Impairment loss on property, plant and equipment	-	-	-	9,869
Incorporation fees	-	-	-	-
(Gain)/loss on foreign currency exchange:				
- unrealised	30	(29)	(153)	(75)
- realised	(13)	(16)	(104)	(6)
Gain on disposal of property, plant and equipment	-	(12)	(1,516)	(12)
Property, plant and equipment written off	-	-	-	6
Interest income	-	(3)	(11)	(19)
Reversal of impairment loss on trade receivables	-	-	(460)	(25)

Other than the above, the items listed under Appendix 9B Note 16 of the Listing Requirement of Bursa Malaysia Securities Berhad are not applicable.

**B6. TAXATION**

There is no tax expense as the Group is in a tax loss position.

Domestic income tax is calculated at the Malaysian statutory income tax rate of 25% of the estimated assessable profit for the financial period. In the Budget Speech 2014, the Government announced that the domestic corporate tax rate would be reduced to 24% from the current financial period's rate of 25% with effect from year of assessment of 2016.

**B7. ACCUMULATED LOSSES**

RM '000	As at	As at
	31.03.16	31.12.14
Realised	(112,164)	(107,469)
Unrealised	(1,940)	(2,046)
	<u>(114,104)</u>	<u>(109,515)</u>
Consolidation adjustments	38,813	38,492
<b>Total accumulated losses</b>	<u><u>(75,291)</u></u>	<u><u>(71,023)</u></u>

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**B8. CORPORATE PROPOSAL**

The Company has on 15 September 2015 announced to undertake the following proposals:

- (i) Proposed reduction of the Company's issued and paid-up share capital via cancellation of RM0.15 from the par value of each existing ordinary share of RM0.20 each in the Company pursuant to Section 64 of the Companies Act, 1965 ("Proposed Par Value Reduction");
- (ii) Proposed subscription by the Company of new ordinary shares in Intra Magnum Sdn. Bhd. ("IMSB") representing 75% of the enlarged issued and paid-up share capital in IMSB ("Proposed Subscription");
- (iii) Proposed placement of new shares representing up to 45% of the issued and paid-up share capital of the Company ("Proposed Placement");
- (iv) Proposed diversification of the existing core business of the Group to include the business of Management and Operation of Hotels and Resorts, Property Investment and Hotel Development ("Proposed Diversifications"); and
- (v) Proposed amendments to the Memorandum and Articles of Association ("M&A") of the Company to amend the par value of the existing ordinary shares ("Proposed Amendments").

The above-mentioned proposals were unanimously approved during the Extraordinary General Meeting held on 24 February 2016.

On 28 April 2016, the High Court had granted the order confirming the Proposed Par Value Reduction. The sealed copy of the court order dated 28 April 2016 confirming the Proposed Par Value Reduction had been lodged with the Companies Commission of Malaysia on 6 May 2016. Hence, the Proposed Par Value Reduction has taken effect. Accordingly, the issued and paid-up share capital of Bio Osmo of RM99,732,000 comprising 498,660,000 ordinary shares of RM0.20 each (before the Proposed Par Value Reduction) has been reduced to RM24,933,000 comprising 498,660,000 ordinary shares of RM0.05 each (after the Proposed Par Value Reduction).

A wholly-owned subsidiary, Amshore Holdings Sdn. Bhd. ("Amshore") has on 30 May 2016 entered into a conditional Sale and Purchase Agreement ("the SPA") with Pentas Prisma Sdn. Bhd. ("PRSB") for the disposal of a freehold industrial land together with an industrial complex comprising three (3) industrial buildings with an annexed 2-storey office block and ancillary buildings ("Factory") for a total sale consideration of RM12.0 million and on such terms and conditions as stated in the SPA. Simultaneous with the execution of the conditional SPA, Amshore and PRSB had on 30 May 2016 also executed a conditional tenancy agreement in respect of the factory.

**B9. GROUP BORROWINGS**

The Group did not have any borrowings as at the end of the reporting period.

**BIO OSMO BHD (740838-A)**  
**(Incorporated in Malaysia)**

**B10. STATUS OF UTILISATION OF PROCEEDS**

The proceeds from the Private Placement issue of RM8.66 million (43,300,000 ordinary shares of RM0.20 each), completed on 14 October 2014, are to be utilised as follows:

Purpose	Proposed utilisation as per announcement dated 4 March 2014	Actual utilisation as at 31/03/16	Intended timeframe for utilisation	Balance unutilised	
	RM'000	RM'000		RM'000	%
Working capital					
- purchase of raw material	4,600	4,600	Within 12 months	-	0
- Salary and administrative expenses	2,000	2,000	Within 12 months	-	0
- Maintenance of existing plant and machinery	2,000	1,074	Within 24 months	926	46.3
- Estimated expenses in relation to proposed private placement	60	60	Within 1 month	-	0
<b>TOTAL</b>	<b>8,660</b>	<b>7,734</b>		<b>926</b>	<b>10.69</b>

**B11. MATERIAL LITIGATION**

The Group did not have any material litigation as at the end of the reporting period.

**B12. DERIVATIVE FINANCIAL INSTRUMENT**

The Group did not have any derivative financial instrument as at the end of the reporting period.

**B13. OFF BALANCE SHEET FINANCIAL INSTRUMENT**

As at the end of the financial period and up to the date of this announcement, there is no off balance sheet financial instrument which has a material impact to the financial statement under review.

**B14. DIVIDEND PAYABLE**

No interim dividend has been declared for the current financial period to date.

**B15. LOSS PER SHARE ("LPS")**

	<b>3 months ended</b>		<b>15 months ended</b>	
	<b>31.03.16</b>	<b>31.03.15</b>	<b>31.03.16</b>	<b>31.03.15</b>
Net loss attributable to Owners of the Company (RM '000)	(749)	(999)	(4,268)	(21,126)
Number of ordinary shares in issue ('000)	498,660	498,660	498,660	474,945
Basic LPS (sen)	(0.15)	(0.20)	(0.86)	(4.45)
Diluted LPS (sen)	(0.15)	(0.20)	(0.86)	(4.45)

**B16. AUTHORISED FOR ISSUE**

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 30 May 2016.